About Genvec
Genvec is a Healthcare company based in Gaithersburg (United States) founded in 1992, and was acquired by Precigen in January 2017. The company has 16 employees. The company was acqui-hired. Its focus areas include Life Sciences, Gene Therapy, DNA and dsDNA. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of gene-based vaccines for hearing loss and balance disorders. GenVecs lead product, CGF166, is licensed to Novartis and is currently in clinical development for the treatment of hearing loss and balance disorders. Also designed the respiratory syncytial virus (RSV) vaccine which is available for licensing.
- Headquarters Gaithersburg, United States
- Employees 16
- Stage Public
- SectorsHealthcare
- Website genvec.com
- Social LinkedIn X Facebook
- Acquired by Precigen (Jan 2017)
Funding Insights of Genvec
- Total Rounds 25
- Last Round Grant — $589,058
- Investors Count 3
Latest 10 of 25 funding rounds of Genvec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $589,058 | Grant | – | – | |
| May 2012 | $590,000 | Grant | – | – | |
| Apr 2012 | $596,160 | Grant | – | – | |
| Mar 2012 | $596,160 | Grant | – | – | |
| Jan 2010 | $28M | Post-IPO | – | – | – |
| Sep 2009 | $295,991 | Grant | – | – | |
| Aug 2009 | $2.47M | Grant | – | – | |
| Aug 2009 | $138,699 | Grant | – | – | |
| Aug 2009 | $138,699 | Grant | – | – | |
| Jul 2009 | $600,000 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Genvec
Genvec has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States |
Investor details for Genvec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Genvec
5 dated milestones of Genvec across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Genvec is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $589K.
- Exit Acquired by Precigen.
Competitors of Genvec
Genvec has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Genvec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genvec
Websites that share an audience with Genvec (genvec.com).
Websites whose visitors overlap most with Genvec. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| transgene.fr | 100% | 6.8K | #2,711,242 | View details | |
| valentis.com | 100% | View details | |||
| endo.com | 95% | 10K | #2,323,439 | View details | |
hemispherx.net | hemispherx.net | 95% | #13,055,489 | – | |
| eisai.com | 95% | 74.5K | #534,857 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Genvec
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genvec (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genvec
Genvec was founded in 1992.
Genvec is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Genvec has 16 employees.
Developer of gene-based vaccines for hearing loss and balance disorders. GenVecs lead product, CGF166, is licensed to Novartis and is currently in clinical development for the treatment of hearing loss and balance disorders. Also designed the respiratory syncytial virus (RSV) vaccine which is available for licensing.
Genvec's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Genvec has 4 investors. Key investors include NIH, HHS, Arch Venture Partners, and Precigen.
Yes. Genvec was acquired by Precigen in January 2017.